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The multipotent role of metallothionein in the nervous system  
G.A. Ushakova, Y.P. Kovalchuk10  
Oles Honchar Dnipropetrovsk National University, Dnipropetrovsk, Ukraine  
We provide a commentary on current experimental and theoretical advances and frame our consideration in terms of the possible func-
tions of MT I+II in the nervous system. Metallothioneins (MT) are a family of small cysteine rich proteins, which since their discovery in 
1957 have been implicated in a range of roles including toxic metal detoxification, protection against oxidative stress, and as a metallochap-
erone involved in the homeostasis of both zinc and copper. The most well studied member of the family is the mammalian metallothionein, 
which consists of two domains: a β-domain with 9 cysteine residues and an α-domain with 11 cysteine residues. Despite over half a century 
of research, the exact functions of MT in the nervous system are still unknown. Our studies have shown that the distribution of MT-I+II in 
the brain after prolonged intoxication, inhalation of 0.1% CdCl2 for 1 hour twice a week over 19 weeks, is dependent on the part of the brain. 
The metallothionein level declines more than 4 times in the hippocampus 3 weeks after continuous intoxication of 0.1% CdCl2. The level of 
MT-I+II in the cerebral cortex decreased by 1.5 times compared with the control group and did not change significantly in the cerebellum 
and thalamus/hypothalamus. The results of an experimental model of postoperative pain indicated that injection with MT-II prevents the 
development of postoperative hyperalgesia in response to mild alteration of physiological activity. Activation of locomotory and exploratory 
activity, and decrease of anxiety in rats under MT-II treatment at 100 µg/rat manifests itself on the 4th day after surgery. Our experimental 
data indicate the multipotent function of MT I+II in the rat brain both as a metal detoxifier and as an inhibitor of postoperative pain.  
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Мультипотентна роль металотіонеїну в нервовій системі 
Г.О. Ушакова, Ю.П. Ковальчук 
Дніпропетровський національний університет імені Олеся Гончара, Дніпропетровськ, Україна 
Наведено коментар про сьогоденні експериментальні та теоретичні досягненя в рамках розуміння можливих функцій MT I+II 
в нервовій системі. Металотіонеїни (MT) – родина невеликих протеїнів, збагачених на цистеїн. Із моменту їх відкриття в 1957 році 
для цих протеїнів визначено функції різного діапазону, включаючи детоксикацію металів, захист від окислювального стресу, і як 
металошаперони вони беруть участь у гомеостазі цинку та міді. Найкраще вивчені металотіонеїни ссавців, які складаються з двох 
доменів : α-області з 11 залишками цистеїну та β-домену з 9 залишками цистеїну. Незважаючи на понад півстоліття досліджень, 
точні функції МТ у нервовій системі донині невідомі. Наші дослідження показали, що розподіл MT I+II у мозку після тривалої 
інтоксикації (вдихання 0,1% CdCl2 протягом години двічі на тиждень упродовж 19 тижнів) залежав від відділів мозку. Рівень мета-лотіонеїну знижується більше ніж учетверо в гіпокампі через 3 тижні після безперервної інтоксикації 0,1% CdCl2. Рівень MT I+II у корі головного мозку знизився в 1,5 раза порівняно з контрольною групою, але не було значних змін у мозочку і таламусі / гіпота-
ламусі. Завдяки експериментальній моделі післяопераційного болю, отримані результати показали, що ін’єкції з MT II запобігають 
розвитку післяопераційної гіперчутливості до болю відповідно до зміни фізіологічної активності. Активація рухової активності та 
зниження занепокоєння при застосуванні МТ II у дозі 100 мкг/щура вже визначалася на четверту добу після операції. Отримані 
експериментальні дані свідчать про мультипотентність функцій MT I+II у мозку щурів: як детоксиканта, так і як інгібітора після-
операційного болю.  
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Introduction  
The first health effect of cadmium (Cd) was lung 
damage, reported in workers already in the 1930’s, while 
bone effects and proteinuria were reported in the 1940’s. 
After World War II, a bone disease with fractures and 
severe pain, the itai-itai disease, a form of Cd-induced 
renal osteomalacia, were identified in Japan (Kazantzis, 
2004). Subsequently, the toxicokinetics and toxicodynam-
ics of Cd were described including its binding to the pro-
tein metallothionein. Cd is classified as a human carcino-
gen causing tumors of the lung, prostate, and other tissues. 
Human activity has markedly increased the distribution of 
Cd in the global environment. Food is the major source of 
Cd exposure for the general population, and cigarette 
smoking significantly adds to the burden of Cd on the 
body. Occupational exposures are mainly from Cd fume 
inhalation, the cadmium-nickel battery industry, electro-
plating, and paint pigments (Liu et al., 2007).  
In search of the component which is responsible for the 
natural accumulation of cadmium in the kidneys of mam-
mals, in 1957 Margashes and Vallee discovered metal-
lothioneines (Margoshes and Vallee, 1957). This family of 
low-proteins is localized in the cytoplasm and nucleus. To-
day, many results about metal-binding proteins have been 
obtained, but these data are still not enough to fully under-
stand the molecular mechanism of participation of these 
proteins in normal and damaging factors. International 
warnings of health risks from cadmium pollution were is-
sued in the 1970’s (Nordberg et al., 1975). WHO, 1992, 
identified renal dysfunction as the critical effect and a crude 
quantitative evaluation was presented (Groten et al., 1994). 
In the 1990’s population groups in China exposed to Cd via 
rice were studied and new information on skeletal, renal 
and reproductive toxicity of Cd was obtained in the Chi-
naCad project. There was a decrease in Bone Mineral Den-
sity (BMD), an increased prevalence of fractures and an 
increased urinary content of marker proteins of renal dys-
function among persons with long term exposure to Cd. 
The development of such biomarkers can be seen as a result 
of applied 'proteomics' research. Variations in metal-
lothionein gene expression were related to development of 
renal dysfunction, supporting the usefulness of this 'ge-
nomic' approach. The ongoing rapid development of 'ge-
nomics' and 'proteomics' technologies will improve possibili-
ties for molecular epidemiology studies in the future, provid-
ing even a better basis for preventive action. In many coun-
tries, Cd exposures are now under better control than in the 
past. The target for the 21st century is to achieve a totally 
acceptable exposure situation without adverse health effects 
from Cd. More details about cadmium and health in the 21st 
century are presented in the review by Nordberg (2004).  
Metallothionein gene expression is transcriptionally 
regulated by dietary zinc too (as by cadmium) and thus 
could serve as an assessment parameter based on zinc-
dependent function. Zinc status is difficult to evaluate in 
humans. Sullivan and Cousins used semiquantitative re-
verse transcriptase-polymerase chain reaction (RT-PCR) 
to establish that MT mRNA is increased in a human 
monocytic cell line by addition of zinc to the medium 
(Sullivan and Cousins, 1997). The RT-PCR data show 
that there was a significant increase in monocyte 
MT mRNA in subjects within 6 d of zinc supplementa-
tion, which remained elevated at d 15 of supplementation. 
In contrast, plasma zinc was greater at d 6 of zinc supple-
mentation, but by d 15 of supplementation, while still 
elevated, was close to control levels. These data suggest 
that monocyte MT mRNA levels respond to zinc supple-
mentation and that the response could serve as a more 
useful assessment variable than plasma zinc for the meas-
urement of zinc status in humans.  
Materials and methods  
Two different experiments were performed using adult 
Wistar rats weighting 250–280 g. Animals were kept in 
the animal house under standard conditions with con-
sumption of water and food ad lib during whole experi-
mental period. All experimental protocols and handling of 
the animals were approved by the local authorities (Dni-
propetrovsk, Ukraine).  
The model of long-lasting intoxication with cadmium 
was induced by inhalation of 0.1% CdCl2 dispersed in air 
during 19 weeks, twice a week, 1-h-long sessions (n = 7). 
The control animals (n = 7) were in the same condition 
without inhalation.  
The experimental model of postoperative pain was 
developed due to Brennan (Brennan et al., 1996). Oper-
ated rats were anaesthetized with ether. The plantar aspect 
of the hindpaw was prepared in a sterile manner with io-
dine solution. A 1 cm longitudinal incision was made with 
a SM65 blade through the skin and fascia of the plantar 
aspect of the foot, starting 0,5 cm from the proximal edge 
of the heel and extending towards the toes. After haemo-
stasis with gentle pressure, the skin was apposed with 
2 mattress sutures of 3 nylon on an FS-2 needle. 
The wound site was covered with iodine solution and a 
mixture of polymixin B and neomycin ointment. After 
surgery, the animals were allowed to recover in the cages. 
The study has been approved by animal protection au-
thorities. Wistar rats were divided into 4 groups: 1 – con-
trol, without any treatment (n = 8); 2 – incision (n = 8); 
3 – injection by 0.2 ml physiological solution containing 
48 µg MT-I+II per animal during 2 days after incision 
(n = 8); 4 – injection by 100 µg MT-I+II per animal dur-
ing 2 days after incision (n = 6).  
Behavioural testing was performed by the open field 
test (Koob et al., 2006).  
Isolated different brain parts were homogenized in  
10-times volume of buffer containing 25 mM tris-HCl, 
pH 7.4, 1 mM EDTA, 2 mM ditiotreytol, 0.2 mM PMSF 
and 0.01 M mertiolate. All procedures were performed at 
+4 ºC. The homogenates were centrifuged at 100 000 g 
during 60 minutes. Supernatants were used to analyse the 
MT-I+II with solid phase competition immuno-enzyme 
analysis with monospecific polyclonal antisera against 
MT-I+II (DAKO, Denmark) and highly purified MT-I+II 
(Sigma) as a marker. Optical density was measured with 
the help of Anthos-2010 absorbance reader (Anthos Lab-
tec Instruments, Austria).  
Statistical analysis was performed using Statistica 
software (version 5, StatSoft, Tulsa, OK, USA). The two-
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tailed nonparametric Kolmogorov-Smirnov test and pa-
rametric Student’s t-test were used to assess the differ-
ences between samples (P < 0,05 was considered to indi-
cate statistical significance).  
Results and discussion  
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The structure and nomenclature of metal-
lothioneins (MTs) 
Metallothioneins consisting of 61–62 amino acids 
without aromatic amino acids and histidine, cysteine resi-
dues are 25–30%. The molecular weight of these proteins 
is 6.5–7.0 kDa. MTs show a considerable level of poly-
morphism while they possessed an exceptional number of 
homology, which shows a high conservative primary 
structure. Metallothioneins have been identified in many 
organisms: fungi, plants, spiders, animals, including hu-
mans (Simpkins, 2000). Using the method of polymerase 
chain reaction (PCR) the gene sequence of MT was iso-
lated. This gene has two introns (575 and 602 bp) and 
three exons (22, 77 and 78 bp) (Fig. 1).  
In humans, the MT genes are tightly clustered in the 
q13 region of chromosome 16 (West et al., 1990), consist-
ing of 7 functional MT-I genes (MT-1A, -B, -E, -F, -G, -H 
and -X) and a single gene encoding each of the other MT 
isoforms, namely MT-II (the MT-2A gene), MT-III and 
MT-IV. High metallothionein conservative structure in 
the evolution and wide distribution shows the importance 
of fundamental physiological functions, despite the fact 
that the nature of MT is still discussed. 
 
  
Fig. 1. Metallothionein genes distribution in mammalians 
Metallothionein domains of different origins, exhibiting 
distinct, highly conserved cysteine positions, show differ-
ences in metal-cysteine coordination and reactivity. Munoz 
et al. (2000) showed the possible influence of (1) the position 
of the cysteine residues and (2) the steric and electrostatic 
effects of neighboring amino acids on the folding and stabil-
ity of MT clusters have been examined with the native lob-
ster beta C and beta N domains, each having nine cysteines 
and binding three M2+ ions, and a modified domain beta  
C → N, in which the cysteines of the C-terminal domain are 
relocated so they are spaced as in the N-terminal domain. 
Each has been synthesized and characterized by UV, CD, 
113Cd NMR, and 1H NMR spectroscopies. The synthetic 
native domains (Cd3 beta C and Cd3 beta N) displayed spec-
troscopic properties, metal-binding affinities, and kinetic 
reactivity similar to those of the holo protein. In contrast, the 
modified Cd3 beta C → N domain was unusually reactive 
and, in the presence of Chelex, a metal-ion chelating resin, 
was converted to a Cd5(beta C → N)2 dimer. These differ-
ences in structure and reactivity demonstrate that the re-
quirements for formation of a stable type-B, Cd3S9, beta clus-
ter are more stringent than simply the sequential positions of 
the cysteines along the peptide chain and include specific 
interactions with neighboring amino acids. Molecular me-
chanics calculations suggest that changes of even a single 
amino acid in lobster Cd3 beta N toward lobster Cd3 beta  
C → N or in mammalian MT1 or MT2 toward Cd3 beta-
MT3 (GIF) can destabilize their structures. Now many stud-
ies are being conducted to understand the mechanism of 
metal binding MT which is important to know the exact 
structure of the active site of this protein.  
There are two main types of metallothioneins isoform: 
MT-I and MT-II. They differ in amino acid composition and 
are separated by DEAE-ion exchange chromatography or 
gel-penetrating HPLC. Separation of DNA gives us informa-
tion that there are two types or more genes for metal-
lothioneins that can be presented as iso-MT, which were 
identified in tissue extracts (Danielyan et al., 2007). For to-
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day, there are four known MT isoforms: MT-I, MT-II – in 
epithelial tissues (skin, intestinal mucosa, liver), MT-III – in 
the brain, MT-IV – epithelium of tongue, gastrointestinal 
tract (Quaife et al., 1994). More than 17 subtypes of metal-
lothioneins have been selected by chromatography, but only 
ten of them supposedly "function" in the human body (Vasak 
and Hasler, 2000).  
The biosynthesis of metallothionein is controlled by 
complex processes. One of these processes – the action of 
metals. Apparently, copper and other metals with zinc re-
placing existing microtubules can promote the genes of this 
protein. The other process is a control diet. When the dietary 
supply of zinc and copper is increased enough to induction 
the MT occurred (primarily in liver and intestine), metal-
lothionein is synthesized quickly and resists the toxic effects 
of zinc (detoxication). It is generally accepted that the ex-
pression of MT-I/II proteins is highly inducible in response 
to a range of stimuli, including metals, hormones, cytokines, 
oxidative agents, inflammation and stress. Mt-1 and Mt-2 
genes are co-ordinately regulated in mice by metals and glu-
cocorticoids. Metal induced synthesis is mediated through 
the action of short cis-acting DNA sequences known as 
metal responsive elements (MREs), which are present in the 
promoter region of all mammalian MT genes (Radtke et al., 
1993), and is mediated mainly by metal response element-
binding transcription factor (MTF-1), a zinc sensitive trans-
acting factor (Andrews, 2000).  
Metallothioneins are relatively rapidly degrading pro-
teins. Twenty-four hours is enough to reduce the pool of 
MT-bound zinc to insignificant levels. It is known that cad-
mium and zinc-binding (2 : 1) MT is 3.5 half-day period.  
Zn-MT is more resistant to degradation, rather than Cd-MT. 
Foremost is the lysosomal degradation of MT (Bremner, 
1987).  
The role of metallothioneins in the nervous system  
The previous studies have suggested that zinc deficiency 
may decrease, whereas the addition of zinc or cadmium can 
increase the expression of metallothionein in the brain, as 
well as MT-I mRNA and MT-III mRNA in the hippocam-
pus, more stress can provoke even greater increase in the 
expression of these proteins. Chen et al. (2005) studied the 
effects of different doses of zinc on the expression of metal-
lothionein isoforms in the hippocampus of stressed rats.  
In the zinc deficiency group, plasm zinc content was de-
creased, while in zinc complementarity group it was slightly 
increased. On the one hand, the expressions of metal-
lothionein in the brain and MT-1 mRNA, MT-3 mRNA in 
the hippocampus were downregulated in zinc deficiency 
group, however, their expressions were evidently enhanced 
in stressed zinc deficiency group. On the other hand, induc-
tions of metallothionein and its mRNAs in zinc complemen-
tarity group were increased, furthermore, the stressed zinc 
complementarity group has a more significant yield of metal-
lothionein and it’s mRNAs. In addition, the levels of plasma 
cortisol, IL-6, IL-1 and NO were increased clearly in the zinc 
deficiency group and stressed zinc deficiency group. These 
results suggested that zinc deficiency may decrease while 
zinc complementarities increase the expressions of metal-
lothionein in the brain and MT-1 mRNA, MT-3 mRNA in 
the hippocampus. Moreover, stress can increase their expres-
sions dramatically. The impairment of stress on the body 
may be involved with the nutrition status of zinc, and zinc 
deficiency can lower the body’s resistivity to stress.  
In the brain, the main source of expression of MT-I+II 
are astrocytes (Aschner et al., 2002). Choroids plexus epithe-
lial cells, endothelial cells and membranes can also produce 
this protein. Recent data show that in physiologically normal 
conditions, MT-I+II is distributed both inside and outside the 
cell (protecting neurons) in low concentration, its level in-
creases during postnatal development and during the induc-
tion of metal ions (Ushakova and Kruchinenko, 2009).  
However, our studies have shown the distribution of  
MT-I+II in the brain after prolonged intoxication, inhalation 
by 0.1% CdCl2 1 h twice a week for 19 weeks is dependent 
on the part of the brain. These results do not show a sharp 
increase in the expression of MT-I+II in the studied brain 



























Fig. 2. The distribution of metallothionein-I+II  
in various brain regions of rats under normal conditions  
and after prolonged cadmium intoxication, inhalation  
of 0.1% CdCl2 during 1 h twice a week for 19 weeks:  
H – hippocampus, CC – cerebral cortex, C – cerebellum,  
T-H – thalamus/hypothalamus, TP – total protein;  
n = 7, * – P <0.001, ** – P <0.05 
The metallothionein level declines by more than 4 times in 
the hippocampus 3 weeks after continuous intoxication of 
0.1% CdCl2. The level of MT-I+II in the cerebral cortex de-
creased 1.5 times compared with the control group and did not 
change significantly in the cerebellum and thalamus/hypo-
thalamus. The data obtained suggest that long-term cadmium 
intoxication may overwhelm the biosynthetic resources of 
MT-I+II or lead to a reorganization of the protective mecha-
nisms in astrocytes depending on the structure of the brain. 
Further detailed study of the morphology of astrocytes and the 
distribution of astrocyte-specific proteins, along with other 
metal-binding proteins, will provide an opportunity to under-
stand the phenomenon of reducing the expression of MT-I+II 
in the hippocampus after chronic cadmium intoxication.  
During last decade many results highlight the important 
role of MT-I/II in coping with brain damage. Many studies 
have clearly demonstrated a similar essential role in coping 
with damage elicited by kainic acid induced seizures, the 
gliotoxin 6-aminonicotinamide, 6-hydroxydopamine, mu-
tated Cu,Zn-superoxide dismutase, multiple sclerosis models, 
traumatic brain injury (Giralt et al., 2002), and transgenic  
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IL-6-induced neuropathology. The overall results obtained in 
these studies are compatible with a role of MT-I/II in de-
creasing oxidative stress, inflammation and apoptosis in the 
CNS, which is in accordance with the results in other tissues 
(Ushakova and Kruchinenko, 2009). It is worth noting again 
that besides being potent antioxidant proteins, MT-I/II are 
induced by oxidative stress (Andrews, 2000), MT induction 
in response to amyloid plaques/production has been demon-
strated in three different mouse models of Alzheimer disease, 
and thus there are suitable models for analyzing the putative 
neuroprotective role of MTs.  
In our study we assessed the physiological and bio-
chemical changes that develop in response to noxious pe-
ripheral stimulation after incision (postoperative pain) under 
metallothionein-II effect.  
The mechanical sensitivity of a surgical incision is the 
most important property that provides both peripheral and 
central pathways of pain mechanisms. Damage to peripheral 
tissue and injury to nerves typically produce persistent pain 
and hyperalgesia. The peripheral component is believed to be 
associated with peripheral inflammation due to different 
substances released in response to surgical trauma. That is 
connected with activation of second messenger systems and 
triggering of the immune system. The central pathways of 
pain are induced by sensitization of dorsal horn neurons by 
noxious stimuli. Today we have a good characterized 
mechanism of neuron sensitization under pain condition, the 
role of specific receptors, there is a molecular structure, type 
of agonists and antagonists (Yajima et al., 2005). However, 
if the peripheral inflammation caused by surgical incision 
plays a crucial role in postoperative pain, it is logical to 
speculate that synthesis induction (or additional injection) of 
the endogenous agent that provides antiinflammation reac-
tion is one of the alternative ways to decrease pain without 
strong and prolonged treatment by direct receptors blockader 
to avoid the development of drug tolerance.  
Following this line, our interest was focused on mammal-
ian metallothioneins (MTs), cystein-rich small metal-binding 
proteins that are induced not only by heavy metals (Zn, Cd) 
and other divalent cations (Ca, Mg, Mn) but also by specific 
agents as catecholamines, glucocorticoids, interleukin-6, glu-
cagon, tumor necrosis factor, acute phase response agents (Di 
Silvestro and Joseph, 1995). Many indicated agents take part 
in the peripheral and central pathways of postoperative pain.  
In our study the experimental model of postoperative pain 
was developed due to Brennan (Brennan et al., 1996). During 
the time of the experiment time all animals were kept with a 
normal food and water intake. The weight of the control ani-
mals and rats before surgery was on average 324 ± 25 g. There 
was a small significant decrease in weight during the first 
3 days after incision (283 ± 16, P < 0.05) for rats without addi-
tional treatment. The weight of the rats that obtained  
MT-treatment after surgery did not change compared with the 
control animals during the whole studied postoperative period.  
The tests of locomotion, exploration activity and anxiety 
provide us with the indicators of underlying pain. Over the 6 
days of testing the control rats (1) showed an unchanged 





















           
















































Fig. 3. Frequency of physiological activity of rats in the open field test:  
1 – control, without any treatment (n = 8); 2 – incision (n = 8); 3 – injection by 0.2 ml physiological solution containing 48 µg  
MT-I+II per animal during 2 days after incision (n = 8); 4 – injection by 100 µg MT-I+II per animal during 2 days after incision (n = 6)  
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The highest significant difference was found for the all 
tests for rats (2) on day 1 after surgery. During next 5 days 
locomotive activity including frequency of line cross and 
central square entries returned gradually, however, the con-
trol level was not yet reached at day 6 after incision. 
The open field test revealed a high increase of anxiety during 
6 days after surgery. The frequency of defecation was ele-
vated to 3–5 times during week after incision. Injection of 
MT-II in the dose 48 µg/rat twice per day during 2 days after 
incision induced better recovery of locomotion of treated rats 
compared with the operated animals but there was not so 
much exploration activity and anxiety after incision. Much 
better results were shown for the rats under MT-II treatment 
at a dose of 100 µg/rat twice per day during 2 days after inci-
sion. The results obtained indicate that injection by MT-II 
prevents postoperative hyperalgesia according to mild altera-
tion of all studied physiological tests. Moreover, we can see 
that recovery of locomotion and exploration activity, and 
decrease of anxiety under MT-II treatment by 100 µg/rat was 
already evidence by day 4 after surgery.  
Many cellular events recognized by the system are be-
lieved to be the central event in the initiation of algesion after 
surgerical procedure, in which activation of NMDA recep-
tors plays the key role. Previously it was believed that zinc 
inhibits NMDA receptors at two independent sites: 1) low-
affinity inside zinc-binding site induces the voltage-
dependent inhibition of NMDA-receptors; 2) high-affinity 
outside zinc-binding site promotes the voltage-independent 
inhibition. Later data suggest that tyrosine kinase Src poten-
tiates NMDA-receptors currents by reducing the tonic inhibi-
tion of receptors composed of NR1 and NR2A subunits by 
extracellular zinc (Vander Jagt et al., 2009). The data ob-
tained in our study link two modulator sites of NMDA recep-
tors. Metallothioneins can help to regulate the zinc donation 
to provide efficiency of NMDA inhibition.  
Conclusion 
The protective role of metallothioneins against Cd toxic-
ity can change the level and character of MT distribution in 
the different brain regions subject to acute or chronic Cd 
poisoning.  
Other proposed functions of MT, such as maintaining es-
sential metal (zinc) homeostasis, regulating gene expression, 
tissue regeneration and inhibition of postoperative pain could 
contribute to protection by MT of the nervous system and the 
whole organism.  
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